Response to Central Boost Radiation Therapy in Unresectable Retroperitoneal Sarcoma: A Case Series
In summary, in this small case series of 5 patients, treatment was tolerated well, and excellent local responses were observed regardless of the timing of the central boost. Given the high rates of metastatic disease that developed in responding patients, effective systemic therapy will likely be needed for unresectable RPS treated with aggressive radiation therapy to the central part of the tumor.
Authors
- Peter G. Hendrickson (ORCID: https://orcid.org/0000-0002-3068-9350)
- Danielle Burner (ORCID: https://orcid.org/0000-0003-0893-1793)
- David G. Kirsch (ORCID: https://orcid.org/0000-0002-2086-205X)
- Dan G. Blazer (ORCID: https://orcid.org/0000-0002-7261-9254)
- Diana M. Cardona (ORCID: https://orcid.org/0000-0002-6877-2280)
- Jared Mullins (ORCID: https://orcid.org/0000-0002-7266-6608)
Institutions
- University Health Network (CA)
- University of Toronto (CA)
- Princess Margaret Cancer Centre (CA)
- Duke Medical Center (US)
- Duke University Hospital (US)
Publication Details
- Journal
- Advances in Radiation Oncology
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1016/j.adro.2024.101689
- Citations
- 1
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.42